Thus, combination therapy of OPT-302 (targeting VEGF-C and -D; Opthea, Victoria, Australia) with ranibizumab (targeting VEGF-A) was tested in the Phase IIb trial for wet AMD (NCT03345082), showing greater improvement in visual acuity than ranibizumab monotherapy, and proceeded to Phase III (NCT04757636 and NCT04757610) [109,110]. Here, VEGFA is linked to wet macular degeneration.